
Medibiofarma
Innovative target-based medicinal chemistry
Enabling T-Cell infiltration in cancer
First-in-class small molecules for Crohn’s disease and neurodegeneration
Vision

To make a real difference to the outlook for patients and their families to become a reference European Biotechnology company with the capabilities to develop desperately needed therapies in complex or untreated diseases
Medibiofarma discovers and develops new chemical entities (NCEs) with clinical proof-of-concept data in human patients
All activities are carrie out internally or throughpartnerships with contract research organizations, research centres and universities.
Latest News
-
Asabys-backed Oriva Therapeutics launches to advance novel treatments for women’s health
Read more: Asabys-backed Oriva Therapeutics launches to advance novel treatments for women’s health• Oriva Therapeutics is launched with the support of Asabys, focused on developing innovative therapies in women’s health• The company incorporates two advanced assets from Oncostellae and Medibiofarma, addressing two…
-
Medibiofarma Successfully Completes Phase 2A Clinical Trial of MBF-118 for Fibrotic Crohn’s Disease
Read more: Medibiofarma Successfully Completes Phase 2A Clinical Trial of MBF-118 for Fibrotic Crohn’s DiseaseNavarra, Spain – August 28, 2025 — Medibiofarma is pleased to announce the successful completion of the industrial research project titled “Investigation of Novel Agonists of the PPAR-γ Receptor for the…
